iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/23933151
PELP1: a review of PELP1 interactions, signaling, and biology - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan 25;382(1):642-651.
doi: 10.1016/j.mce.2013.07.031. Epub 2013 Aug 8.

PELP1: a review of PELP1 interactions, signaling, and biology

Brian J Girard  1 , Andrea R Daniel  1 , Carol A Lange  1 , Julie H Ostrander  2
Affiliations
Review

PELP1: a review of PELP1 interactions, signaling, and biology

Brian J Girard et al. Mol Cell Endocrinol. .

Abstract

Proline, glutamic acid, and leucine rich protein 1 (PELP1) is a large multi-domain protein that has been shown to modulate an increasing number of pathways and biological processes. The first reports describing the cloning and characterization of PELP1 showed that it was an estrogen receptor coactivator. PELP1 has now been shown to be a coregulator for a growing number of transcription factors. Furthermore, recent reports have shown that PELP1 is a member of chromatin remodeling complexes. In addition to PELP1 nuclear functions, it has been shown to have cytoplasmic signaling functions as well. In the cytoplasm PELP1 acts as a scaffold molecule and mediates rapid signaling from growth factor and hormone receptors. PELP1 signaling ultimately plays a role in cancer biology by increasing proliferation and metastasis, among other cellular processes. Here we will review (1) the cloning and characterization of PELP1 expression, (2) interacting proteins, (3) PELP1 signaling, and (4) PELP1-mediated biology.

Keywords: AIB1; AR; BCAS3; CBP; CREB binding protein; ChIP; Coactivator; E2; ER; ERRα; Estrogen signaling; Extra-nuclear signaling; FHL2; GR; HDAC; Hormone resistance; IHC; ILK1; KDM1; LIM domain; Lin-1, Isl-1, and Mec-3 domain; MNAR; Modulator of Nongenomic Activity of ER; PELP1; RXR; SH2; SH3; STAT3; TIF2; amplified in breast cancer 1; androgen receptor; breast carcinoma amplified sequence 3; c-Src homology domain 2; c-Src homology domain 3; chromatin immunoprecipitation; estradiol; estrogen receptor; estrogen-related receptor alpha; four and a half LIM domains 2; glucocorticoid receptor; histone deacetylase; immunohistochemistry; integrin-linked kinase 1; lysine-specific histone demethylase 1; proline, glutamic acid and leucine rich protein 1; retinoid X receptor; signal transducer and activator or transcription 3; transcriptional mediators/intermediary factor 2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of PELP1 domain structure.
Figure 2
Figure 2
Targeting PELP1 pathways during tumorigenesis. Diagram of PELP1 signaling complexes and pathways in the cytoplasm and nucleus that could be targeted with pre-clinical and clinical drugs. At the membrane, PELP1 interacting RTKs could be targeted through blocking antibodies such as cetuzimab or kinase inhibitors such as erlotinib (both targeted to EGFR). In the cytoplasm, PELP1 interacting molecules such as Src or PI3K could be inhibited using the small molecule inhibitors dasatanib or perifosine, respectively. In the nuclear compartment, PELP1 interacts with different proteins including KDM1A and CDKs, both of which have candidate therapies available. Finally, exciting pre-clinical data suggest that targeting PELP1 protein-protein interactions may be a viable treatment option, as interfering with the LXXLL motif between PELP1 and AR successfully blocked tumor growth.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer. 2013;13:115. - PMC - PubMed
    1. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem. 2003;278:22119–22127. - PMC - PubMed
    1. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol. 2004;18:1096–1108. - PubMed
    1. Beguelin W, Diaz Flaque MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol. 2010;30:5456–5472. - PMC - PubMed
    1. Beyer C. Estrogen and the developing mammalian brain. Anatomy and embryology. 1999;199:379–390. - PubMed

Publication types

Substances